Latigo Biotherapeutics, Inc. Stock

Stocks

Market Closed - Nasdaq 23:00:00 25/09/2026 +03			5-day change	1st Jan Change
17.15 ^USD	-3.43%		-23.95%	-

09-21	Latigo Biotherapeutics, Inc.(NasdaqGS:LTGO) added to S&P TMI Index	CI
09-04	Latigo Biotherapeutics Q2 Net Loss Narrows	MT

NasdaqUSD

Markets		Quality
Nasdaq	LTGO	Delayed
CBOE	LTGO	Real-time

09-21	Latigo Biotherapeutics, Inc.(NasdaqGS:LTGO) added to S&P TMI Index	CI
09-04	Latigo Biotherapeutics Q2 Net Loss Narrows	MT
09-03	Latigo Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09-01	Jefferies Initiates Latigo Biotherapeutics at Buy With $50 Price Target	MT
09-01	Leerink Partners Initiates Latigo Biotherapeutics at Outperform With $36 Price Target	MT
09-01	Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target	MT
09-01	Goldman Sachs Initiates Latigo Biotherapeutics at Buy With $73 Price Target	MT
08-10	Latigo Biotherapeutics, Inc.(NasdaqGS:LTGO) added to NASDAQ Composite Index	CI
08-07	Latigo Biotherapeutics Shares Rise in Nasdaq Debut	MT
08-07	Latigo Biotherapeutics Prices $345.6 Million IPO	MT
08-06	Latigo Biotherapeutics, Inc. has completed an IPO in the amount of $345.6 million.	CI
05-18	Latigo Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

09-01	Jefferies Initiates Latigo Biotherapeutics at Buy With $50 Price Target	MT
09-01	Leerink Partners Initiates Latigo Biotherapeutics at Outperform With $36 Price Target	MT
09-01	Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target	MT
09-01	Goldman Sachs Initiates Latigo Biotherapeutics at Buy With $73 Price Target	MT

09-03

Manager	Title	Age	Since
Bryan Moyer PRN	Corporate Officer/Principal	-	-
Nima Farzan CEO	Chief Executive Officer	50	22/07/2024
Neha Krishnamohan DFI	Director of Finance/CFO	39	01/02/2026

Director	Title	Age	Since
Nima Farzan BRD	Director/Board Member	50	22/07/2024
Timothy Walbert CHM	Chairman	59	01/10/2024
Sara Bonstein BRD	Director/Board Member	45	01/04/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/10/26 A	Westlake Biopartners LLC	Conversion	Company	25,390,610	36.1805%
8/10/26 A	5AM Venture Management LLC	Conversion	Company	14,651,924	20.8784%
8/10/26 A	Foresite Capital Management LLC	Conversion	Company	18,222,656	25.9665%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LATIGO BIOTHERAPEUTICS, INC.	-3.43%	-23.95%	-	-	1.14B
LONZA GROUP AG	-0.14%	+4.33%	+9.00%	+31.64%	47.97B
IQVIA HOLDINGS INC.	-1.69%	+1.48%	+50.57%	+34.53%	44.5B
REVOLUTION MEDICINES, INC.	+2.56%	+7.34%	+366.69%	+608.26%	43.93B
BEONE MEDICINES AG	+0.24%	+2.85%	+10.67%	+94.47%	41.03B
CELLTRION, INC.	-0.62%	-1.11%	+4.65%	+48.91%	29.85B
MEDPACE HOLDINGS, INC.	-0.28%	+1.07%	+24.58%	+155.58%	17.27B
TEMPUS AI, INC.	+3.37%	+9.21%	+8.32%	-	15.34B
EUROFINS SCIENTIFIC SE	-0.46%	+1.20%	+26.90%	+42.21%	15.3B
ASCENDIS PHARMA A/S	-2.21%	-4.70%	-	-	14.82B
Average	-0.27%	-0.28%	+62.67%	+145.08%	27.12B
Weighted average by Cap.	+0.09%	+2.75%	+79.67%	+160.28%